Zhaoke Ophthalmology Limited (6622.HK)

1.530 +0.010 (+0.66%) At close: 04:08PM HKT

Zhaoke Ophthalmology Limited

No. 1 Meide 3rd Road
Pearl River Industrial Park Nansha District
Guangzhou
China
86 20 3906 2828
https://www.zkoph.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 313

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Xiaoyi Li Ph.D.	Chairman of the Board & CEO	10.76M	N/A	1963
Mr. Xiangrong Dai	Executive Director	781.51k	N/A	1980
Dr. Lit Fui Lau	President & Chief Scientific Officer	N/A	N/A	1964
Ms. Xinyan Feng	Chief Business Officer & CFO	N/A	N/A	1979
Ms. Yang Lei	Group General Counsel	N/A	N/A	1981
Dr. Mauro Bove Ph.D.	Senior Vice President of Corporate Development	N/A	N/A	1955
Mr. Jiang Feng	Senior Vice President of Sales & Marketing	N/A	N/A	1976
Dr. Albert Tsai Jr.	Chief Medical Officer	N/A	N/A	1974
Mr. Guohui Zhang	Senior Vice President of Manufacturing & Logistics	N/A	N/A	1974
Ms. Carol Liu	Group Head of Regulatory Affairs	N/A	N/A	1984

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People's Republic of China. It is developing various drugs that cover ophthalmic indications, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.

Corporate governance

Zhaoke Ophthalmology Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.